Bulletin n°100

Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: Endpoint Selection, Surrogacy, and Quality of Reporting

Journal of Clinical Oncology

Surrogate End Points and Their Validation in Oncology Clinical Trials

Journal of Clinical Oncology

Trends in immunotherapy for brain metastases

The Lancet Oncology

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

The Lancet Oncology

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

The Lancet Oncology

Neoadjuvant chemotherapy for breast cancer: any progress?

The Lancet Oncology

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

The Lancet Oncology

Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

The Lancet Oncology

Anti-CD22 therapy in acute lymphoblastic leukaemia

The Lancet Oncology

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

The Lancet Oncology

Hodgkin's Lymphoma — The Great Teacher

New England Journal of Medicine

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

New England Journal of Medicine

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial

The power of three: hypofractionation, protons, and molecular imaging in glioblastoma radiotherapy

The Lancet Oncology

Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial

The Lancet Oncology

New strategies for patients with limited-stage small-cell lung cancer

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

The Lancet Oncology

Palbociclib: a new partner for cetuximab?

The Lancet Oncology

Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes

Journal of the National Cancer Institute

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

Journal of the National Cancer Institute

Factors predicting low patient accrual in cancer clinical trials

Journal of the National Cancer Institute

Predicting Low Trial Accrual Mathematically: Is That the Right Emphasis?

Journal of the National Cancer Institute

Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials

Journal of the National Cancer Institute

HER2-positive breast cancer: is more treatment better?

The Lancet Oncology

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

The Lancet Oncology

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology

Pathological complete remission and long-term outcome - what do we know in 2016?

The Lancet Oncology

Novel trial designs for high-risk myelodysplastic syndromes

The Lancet Oncology

Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention

New England Journal of Medicine

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

New England Journal of Medicine

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

The Lancet

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The Lancet Oncology

Targeting HER2: precision oncology for colorectal cancer

The Lancet Oncology

Mantle cell lymphoma treatment: plus ça change...

The Lancet

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Science

Cancer therapies that are gone with the Wnt

Science

Cardiovascular disease after Hodgkin's lymphoma: a role for screening

The Lancet Haematology

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

The Lancet Haematology

EGFR mutations and EGFR tyrosine kinase inhibitors

The Lancet Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

The Lancet Oncology

Monoclonal Antibodies in Multiple Myeloma Come of Age

New England Journal of Medicine

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

New England Journal of Medicine

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

The Lancet Haematology

Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor ChemotherapyA Systematic Review and Meta-analysisHBV Reactivation in Solid Tumors

Annals of Internal Medicine

Evaluating Hepatitis B Virus Reactivation During Solid Tumor Chemotherapy: Evidence to Guide Pretreatment Hepatitis B Screening and ProphylaxisEvidence to Guide Pretreatment Hepatitis B Screening and Prophylaxis

Annals of Internal Medicine

Immunotherapy: the next step in the treatment of myeloma

The Lancet Haematology

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

Nature

Cancer immunotherapy: Dendritic-cell vaccines on the move

Nature

Nivolumab: another weapon in the growing immunotherapy arsenal

The Lancet Oncology

Nilotinib, imatinib, and GIST therapy

The Lancet Oncology

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial

The Lancet Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology

Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer

Journal of Clinical Oncology

Observation for Clinically Localized Prostate Cancer

Journal of Clinical Oncology

Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations

Journal of Clinical Oncology

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Journal of Clinical Oncology

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology

Cetuximab or bevacizumab in metastatic colorectal cancer?

The Lancet Oncology

Towards effective adjuvant treatment for urothelial cancer

The Lancet Oncology

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

The Lancet Oncology

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

Journal of Clinical Oncology

Adjuvant therapy for colon cancer: Small steps toward precision medicine

JAMA Oncology

Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: Secondary analysis of NSABP C-07/NRG oncology randomized clinical trial

JAMA Oncology

Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer

Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer

ICON-6: the danger of changing study design midstream

The Lancet

Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: A subgroup analysis of a randomized clinical trial

JAMA Oncology

Treatment of renal cell cancer with programmed cell death 1 blockade: How much is enough?

JAMA Oncology

New options in treatment of advanced renal cancer

The Lancet Oncology

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

The Lancet Oncology

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet

Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma

The Lancet

Combination chemotherapy for relapsed small-cell lung cancer

The Lancet Oncology

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

The Lancet

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology

Palliative chemotherapy for patients with breast cancer

The Lancet Oncology

THe juxtaposition of population science and individual treatment recommendations for intermittent androgen deprivation therapy

JAMA Oncology

Intermittent vs continuous androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis

JAMA Oncology

Postprogression prolongation of survival in EGFR-mutated lung cancer: Reconciling the aspiration and impress trials

JAMA Oncology

First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in asian patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer: The aspiration study

JAMA Oncology

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

The Lancet

Gemcitabine-resistant pancreatic cancer: a second-line option

The Lancet

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

The Lancet Oncology

Targeting the microenvironment in ovarian cancer

The Lancet Oncology

No Pain, No Gain: A Fallacy So Far

Journal of Clinical Oncology

Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial

Journal of Clinical Oncology

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

Journal of Clinical Oncology

End of Rituximab Maintenance for Low–Tumor Burden Follicular Lymphoma

Journal of Clinical Oncology

Therapeutic Properties of Aerobic Training After a Cancer Diagnosis: More Than a One-Trick Pony?

Journal of the National Cancer Institute

Modulation of Blood Flow, Hypoxia, and Vascular Function in Orthotopic Prostate Tumors During Exercise

Journal of the National Cancer Institute

Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality

Journal of Clinical Oncology

Is Early Hematopoietic Stem-Cell Transplantation Necessary in Mantle-Cell Lymphoma?

Journal of Clinical Oncology

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Journal of the National Cancer Institute

Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts

Journal of the National Cancer Institute

Beyond Exon 2 — The Developing Story of RAS Mutations in Colorectal Cancer

New England Journal of Medicine

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

New England Journal of Medicine

Conceptual and Technical Challenges in Network Meta-analysis

Annals of Internal Medicine

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

BMC Medicine

Can we improve ABVD in Hodgkin's lymphoma?

The Lancet Oncology

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

The Lancet Oncology

New options for second-line therapy of advanced renal cancer

The Lancet Oncology

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

The Lancet Oncology

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

The Lancet Oncology

PrefHer: finally addressing the preferences of her, too

The Lancet Oncology

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

Journal of the National Cancer Institute

Overcoming Resistance to MAPK Pathway Inhibitors

Journal of the National Cancer Institute

Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

Journal of Clinical Oncology

Oxaliplatin As Part of Adjuvant Therapy for Colon Cancer: More Complicated Than Once Thought

Journal of Clinical Oncology

Aromatase inhibitors and musculoskeletal adverse events

The Lancet Oncology

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2?3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

The Lancet Oncology

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

The Lancet Oncology

Maintenance chemotherapy in advanced non-small-cell lung cancer

The Lancet Oncology

Genetic and Pharmacologic Inhibition of

Targeting